Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. The most common form of CLL arises from B-cell lymphocytes, with rarer subtypes including prolymphocytic leukemia (PLL), large granular lymphocyte (LGL) leukemia, and hairy cell leukemia (HCL). Since ibrutinib’s first approvals in 2014, the growing dominance of BTK inhibitors and other key therapies targeting CD20, BCL-2, and PI3K in 1st-line and R/R CLL has increasingly eroded the role of chemoimmunotherapy and other older, less tolerable treatments. Current areas of interest include evaluating combinations of key drug class members, optimal treatment durations and sequencing, and MRD-guided strategies.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in chronic lymphocytic leukemia to help guide strategic and tactical commercial development decisions for market participants.